P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI
B E Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), H Zhang(Janssen (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Gert Van Assche(KU Leuven), Silvio Danese(IRCCS Ospedale San Raffaele), Stephan R. Targan(Cedars-Sinai Medical Center), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), Philippe Szapary(Cedars-Sinai Medical Center), Chris O’Brien(Neurocrine Biosciences (United States)), Ramesh Arasaradnam(University Hospital Coventry), Jewel Johanns(Johnson & Johnson (United States)), Rupert W. Leong(The University of Sydney)
Cited by 5
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k